Navigation Links
Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
Date:10/30/2010

Pharmaceuticals is a global pharmaceutical and research development company. The Company's main research and development facilities are in Beerse, Belgium with offices in Titusville, NJ and Cork, Ireland. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS and hepatitis C drugs, and anti-infectives for diseases of high unmet medical need. Tibotec Pharmaceuticals is a subsidiary of Johnson & Johnson.

(1) World Health Organization (2002). Hepatitis C. Retrieved October 26, 2010 from http://www.who.int/csr/disease/hepatitis/Hepc.pdf.

(2) Hepatitis C: Global Prevalence. Weekly Epidemiological Record. 1997;72 : 341-8. Retrieved October 26, 2010 from http://www.who.int/docstore/wer/pdf/1997/wer7246.pdf.  

(3) Roche B, Samuel D., Villejuif, France. Risk factors for hepatitis C recurrence after liver transplantation.  J Viral Hepat. 2007 Nov;14. Suppl 1:89-96.  Contacts: Media

Investor RelationsKaren Manson : Cell + 32 (479) 89 47 99

Stan Panasewicz : +1 732 524 2524
'/>"/>

SOURCE Tibotec Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
4. LPBP Inc. - Re-filing certification of interim filings
5. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
6. Arpida Reports Interim Results for Six Months to 30 June 2008
7. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
8. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
9. Misonix Announces Interim Distribution Agreement for Italy
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013 Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... serious infectious diseases, announced today that Jeffrey Riley , ... New York Conference on Thursday, June 27, 2013 at The ... Mr. Riley is scheduled to present at 8:40 a.m. (Eastern ... can be accessed by logging onto the web at ...
(Date:6/19/2013)... WASHINGTON, D.C. (PRWEB) June 19, 2013 ... with its first Bayer Bee Care Community Leadership Award. ... Pollinator Week Congressional Reception in Washington, D.C., an ... pollinators make to the world’s food supply. , ... who have harnessed the power of the honey bee ...
(Date:6/19/2013)... Bloomington, Indiana (PRWEB) June 19, 2013 ... Valentine joined the speaking faculty at 2013’s BioLogistics ... , The conference, coordinated by Cold Chain IQ ... surrounding biologics. This “complexity” is, in part, attributed ... medicine. , “Implicit within these trends is ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Express Diagnostics ... tests, today announced that it has received Class III ... and sell its DrugCheck® NxStep Onsite Drug Screen ... of the rapid screening device in near-patient settings, such ... Screen Cup received Health Canada Class III approval for ...
Breaking Biology Technology:Synthetic Biologics to Present at OneMedForum New York 2013 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... Site, ST. LOUIS, Jan. 14 SAFC(R), ... ), has announced its plans for a $12,million ... Carlsbad,California. Two new fully segregated state-of-the-art viral product,manufacturing ... in disposable,bioreactor technologies and enable SAFC Pharma,s(TM) viral ...
... underpin compact LED multiplexing module, SANTA ROSA, ... ), a leading provider of optical components for ... its ZoroLight(TM) LED,multiplexing technology. The compact LED combining ... for bio-analytical,applications and medical instrumentation. The ZoroLight LED ...
... VIRxSYS Corporation, a,privately held company developing gene therapies ... privately-owned biotechnology company,focused on the manufacture and development ... to settle the pending litigation between,the two companies. ... in the lawsuit, which has been pending in ...
Cached Biology Technology:SAFC Pharma to Increase Viral Product Manufacturing Capacity 2SAFC Pharma to Increase Viral Product Manufacturing Capacity 3Bookham to Enter Biomedical Illumination Market 2Bookham to Enter Biomedical Illumination Market 3VIRxSYS and Lentigen Announce Litigation Settlement 2
(Date:6/19/2013)... Agency (EMA) approved the modified adeno-associated virus AAV-LPL ... clinical use in the Western world. uniQure, a ... the treatment of a rare inherited metabolic disease ... one or two out of one million people. ... pancreas. Afflicted individuals carry a defect in the ...
(Date:6/18/2013)... has been awarded a $394,300 grant from the ... and flow in the new facilities of the ... Arlington associate professor of civil engineering, will investigate ... to the water in an effort to eliminate ... pipelines. Adding monochloramine is widely practiced throughout the ...
(Date:6/18/2013)... Obar, Ph.D., Department of Immunology and Infectious Diseases, Montana ... Young Investigator Award for his research on factors affecting ... , Obar earned his B.A. in Microbiology from ... complete his Ph.D. in Microbiology and Immunology from Dartmouth ... research in Edward Usherwood,s laboratory at the Geisel School ...
Breaking Biology News(10 mins):No danger of cancer through gene therapy virus 2UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2The American Society for Microbiology honors Joshua Obar 2
... will award seed money grants of up to ... explore alternative energy innovations for transportation. Each project ... have strong potential to eventually attract external funding ... "Partnerships between U-M and a world-class research and ...
... VistaGen Therapeutics and the Wisconsin Alumni Research Foundation ... cell patents for the development and commercialization of stem ... in South San Francisco, is one of the world,s ... cell technology to transform the ways drugs are discovered ...
... of a straightforward experiment, researchers have provided some clues ... organic molecules came together to form the basis of ... week in JBC , demonstrated how ancient RNA ... RNA, the single-stranded precursor to DNA, normally expands one ...
Cached Biology News:VistaGen, WARF sign license agreement for human embryonic stem cell technology 2
... Epithelial and endothelial cells-directed ... a RGD peptide-conjugated polyethylenimine which ... integrin-expressing epithelial and endothelial cells. ... in cell-cell and cell-matrix adhesion ...
... WinMelt software is used to ... any DNA sequence up to ... optimizing placement of primers and ... by denaturing gradient gel electrophoresis ...
Request Info...
... Accurate To score SNPs, ... sequencing, the gold standard in DNA analysis. ... The polymorphic locus can be confirmed by ... DNA sequencing also provides sequence context information, ...
Biology Products: